🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness

RecruitingPhase 1Ages 25 Years - 75 YearsAllUniversity Hospital, Basel, Switzerland
NCT06796361 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Psilocybin (active compound of "magic mushrooms") is a prototypical psychedelic substance that acts via agonism on serotonin (5-HT) 2A receptors. Psilocybin is rapidly metabolized into its active metabolite psilocin. Psilocybin is currently under investigation as potential treatment for various neuropsychiatric disorders. Psilocybin is also widely used for recreational purposes and as research tool in neuroscience. Besides its current clinical development, a clear characterization of the dose-response relationship of psilocybin is lacking. With the present study the investigators aim to close this knowledge gap by administering low (5mg) to high (40mg) single doses of psilocybin to healthy participants. Besides its agonism on 5-HT2A receptors, psilocin also binds to other receptors and inhibits serotonin transporters (SERT). To this data only few studies have investigated these effects a

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age between 25 and 75 years. 2. Sufficient understanding of the German language. 3. Understanding the procedures and the risks that are associated with the study. 4. Participants must be willing to adhere to the protocol and sign the consent form. 5. Participants must be willing to refrain from taking illicit psychoactive substances during the study (not including cannabis). 6. Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration. 7. Women of childbearing potential must be willing to use effective birth-control throughout study participation Exclusion Criteria: 1. Chronic or acute medical condition, including a history of seizures. 2. Body mass index 18-29.9 kg/m2 3. Current or previous major psychiatric disorder (e.g. psychotic disorders, mania / hypomania, anxiety disorders). 4. Psychotic or bipolar disorder in first-degree relatives, not including psychotic disorders secondary to an apparent medical reason, e.g., brain injury, dementia, or lesions of the brain. 5. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg) 6. Psychedelic substance use (with the exception of cannabis) more than 20 times or any time within the previous two months 7. Pregnant or nursing women. 8. Participation in another clinical trial (currently or within the last 30 days). 9. Use of medications that may interfere with the effects of the study medications (any psychiatric medications and any medication with known to interact with the study substances). 10. Tobacco smoking (\>10 cigarettes/day). 11. Consumption of alcoholic drinks (\>15 drinks / week). 12. Body weight \< 45 kg.
💊

What it tests

  • Ketanserin 40mg plus Psilocybin 40mg
  • 40mg Psilocybin
  • 20mg Psilocybin
  • 10mg Psilocybin
  • 5mg Psilocybin
📍

Where

1 site
Clinical Trial Unit
Basel, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy